<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04417569</url>
  </required_header>
  <id_info>
    <org_study_id>2002-ABU-001-CC</org_study_id>
    <nct_id>NCT04417569</nct_id>
  </id_info>
  <brief_title>A Proof of Concept Study of Serum Progesterone Levels for IVF/ICSI Following HCG Trigger for Oocyte Maturation</brief_title>
  <official_title>A Proof of Concept Study to Determine the Rise of Progesterone Levels After Human Chorionic Gonadotrophin (hCG) Trigger in Stimulated Cycles of IVF/ICSI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ART Fertility Clinics LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ART Fertility Clinics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the rise of progesterone levels after human chorionic gonadotrophin&#xD;
      (hCG) trigger in stimulated cycles IVF/ICSI&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have suggested that controlled ovarian hyperstimulation adversely affects endometrial&#xD;
      receptivity. In ovarian stimulation cycles with exogenous gonadotrophins there is an ongoing&#xD;
      debate regarding the effect of a late follicular phase progesterone level on reproductive&#xD;
      outcomes. It is not yet clarified if an elevated serum progesterone level in the late&#xD;
      follicular phase is a symptom or cause of an adverse effect on reproductive outcomes. A new&#xD;
      hypothesis is evolving and gaining momentum providing a novel explanation for the association&#xD;
      between late follicular phase progesterone rise and reproductive outcome. It is proposed that&#xD;
      exogenous FSH (Follicle-stimulating hormone) administration results in supraphysiological&#xD;
      levels of FSH, which induce an abundance of LH (luteinizing hormone) receptors on granulosa&#xD;
      cells causing the follicles to become hypersensitive to LH-like activity (ie hCG trigger).&#xD;
      Based on this hypothesis, the focus should be placed on the hCG trigger rather than on the&#xD;
      late follicular phase progesterone rise.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Level of progesterone day of trigger</measure>
    <time_frame>1 day</time_frame>
    <description>day of the hCG trigger between 1000h - 1200h, before trigger, 1 hour after trigger, 2 hrs after trigger</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of progesterone day of egg retrieval</measure>
    <time_frame>1 day</time_frame>
    <description>36hrs after trigger</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Infertility</condition>
  <condition>Infertility, Female</condition>
  <condition>IVF</condition>
  <condition>hCG</condition>
  <arm_group>
    <arm_group_label>stimulated cycles</arm_group_label>
    <description>Patients will have blood drawn on five separate occasions: before and following hCG trigger on the day of final oocyte maturation and day of egg collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>human chorionic gonadotropin</description>
    <arm_group_label>stimulated cycles</arm_group_label>
    <other_name>human chorionic gonadotropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Endometrial thickness monitoring</description>
    <arm_group_label>stimulated cycles</arm_group_label>
    <other_name>transvaginal scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Progesterone, Luteinizing Hormone, Estradiol</description>
    <arm_group_label>stimulated cycles</arm_group_label>
    <other_name>Progesterone, Luteinizing Hormone, Estradiol</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients who are planned to commence ovarian stimulation for IVF/ICSI with hCG&#xD;
        trigger for oocyte maturation and plan to avail of pre-implantation genetic screening with&#xD;
        embryo vitrification of their biopsied embryos at blastocyst stage&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females aged 18 to 42 years with regular menstrual cycles of 26-34 days&#xD;
&#xD;
          -  Undergoing ovarian stimulation for IVF/ICSI &amp; PGS.&#xD;
&#xD;
          -  Receiving recombinant FSH for stimulation&#xD;
&#xD;
          -  hCG 5000iu IM as trigger injection for oocyte maturation.&#xD;
&#xD;
          -  Ovarian stimulation in GnRH-antagonist protocols&#xD;
&#xD;
          -  BMI 18- 35 kg/m2&#xD;
&#xD;
          -  Having 1 or 2 euploid embryos for transfer in spontaneous natural cycles.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor ovarian reserve as defined by Bologna criteria&#xD;
&#xD;
          -  PCOS in accordance with Rotterdam criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raquel Loja Vitorino, Specialist</last_name>
    <role>Principal Investigator</role>
    <affiliation>ART Fertility Clinics LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Lawrenz, PhD</last_name>
    <phone>+97126528000</phone>
    <phone_ext>1108</phone_ext>
    <email>shieryl.digma@artfertilityclinics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shieryl Digma, RN</last_name>
    <phone>+97126528000</phone>
    <phone_ext>1122</phone_ext>
    <email>shieryl.digma@artfertilityclinics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ART Fertility Clinics LLC</name>
      <address>
        <city>Abu Dhabi</city>
        <zip>60202</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Lawrenz, PhD</last_name>
      <phone>+97102 652 8000</phone>
      <phone_ext>1108</phone_ext>
      <email>shieryl.digma@artfertilityclinics.com</email>
    </contact>
    <contact_backup>
      <last_name>Shieryl Digma, RN</last_name>
      <phone>+97102 652 8000</phone>
      <phone_ext>1122</phone_ext>
      <email>shieryl.digma@artfertilityclinics.com</email>
    </contact_backup>
    <investigator>
      <last_name>Raquel Loja Vitorino, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <results_reference>
    <citation>Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. Hum Reprod Update. 2003 Nov-Dec;9(6):515-22. Review.</citation>
    <PMID>14714588</PMID>
  </results_reference>
  <results_reference>
    <citation>Devroey P, Bourgain C, Macklon NS, Fauser BC. Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. Trends Endocrinol Metab. 2004 Mar;15(2):84-90. Review.</citation>
    <PMID>15036255</PMID>
  </results_reference>
  <results_reference>
    <citation>Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, Devroey P. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril. 2002 Nov;78(5):1025-9.</citation>
    <PMID>12413988</PMID>
  </results_reference>
  <results_reference>
    <citation>Nikas G, Develioglu OH, Toner JP, Jones HW Jr. Endometrial pinopodes indicate a shift in the window of receptivity in IVF cycles. Hum Reprod. 1999 Mar;14(3):787-92.</citation>
    <PMID>10221715</PMID>
  </results_reference>
  <results_reference>
    <citation>Simón C, Garcia Velasco JJ, Valbuena D, Peinado JA, Moreno C, Remohí J, Pellicer A. Increasing uterine receptivity by decreasing estradiol levels during the preimplantation period in high responders with the use of a follicle-stimulating hormone step-down regimen. Fertil Steril. 1998 Aug;70(2):234-9.</citation>
    <PMID>9696213</PMID>
  </results_reference>
  <results_reference>
    <citation>Weinerman R, Mainigi M. Why we should transfer frozen instead of fresh embryos: the translational rationale. Fertil Steril. 2014 Jul;102(1):10-8. doi: 10.1016/j.fertnstert.2014.05.019. Epub 2014 Jun 2. Review.</citation>
    <PMID>24890274</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Y, Lee KF, Ng EH, Yeung WS, Ho PC. Gene expression profiling of human peri-implantation endometria between natural and stimulated cycles. Fertil Steril. 2008 Dec;90(6):2152-64. doi: 10.1016/j.fertnstert.2007.10.020. Epub 2008 Jan 14.</citation>
    <PMID>18191855</PMID>
  </results_reference>
  <results_reference>
    <citation>Haouzi D, Assou S, Mahmoud K, Tondeur S, Rème T, Hedon B, De Vos J, Hamamah S. Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients. Hum Reprod. 2009 Jun;24(6):1436-45. doi: 10.1093/humrep/dep039. Epub 2009 Feb 26.</citation>
    <PMID>19246470</PMID>
  </results_reference>
  <results_reference>
    <citation>Roque M, Lattes K, Serra S, Solà I, Geber S, Carreras R, Checa MA. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. Fertil Steril. 2013 Jan;99(1):156-162. doi: 10.1016/j.fertnstert.2012.09.003. Epub 2012 Oct 3. Review.</citation>
    <PMID>23040524</PMID>
  </results_reference>
  <results_reference>
    <citation>Roque M, Valle M, Guimarães F, Sampaio M, Geber S. Freeze-all policy: fresh vs. frozen-thawed embryo transfer. Fertil Steril. 2015 May;103(5):1190-3. doi: 10.1016/j.fertnstert.2015.01.045. Epub 2015 Mar 4.</citation>
    <PMID>25747130</PMID>
  </results_reference>
  <results_reference>
    <citation>Haas J, Smith R, Zilberberg E, Nayot D, Meriano J, Barzilay E, Casper RF. Endometrial compaction (decreased thickness) in response to progesterone results in optimal pregnancy outcome in frozen-thawed embryo transfers. Fertil Steril. 2019 Sep;112(3):503-509.e1. doi: 10.1016/j.fertnstert.2019.05.001. Epub 2019 Jun 24.</citation>
    <PMID>31248618</PMID>
  </results_reference>
  <results_reference>
    <citation>Testart J, Frydman R, Feinstein MC, Thebault A, Roger M, Scholler R. Interpretation of plasma luteinizing hormone assay for the collection of mature oocytes from women: definition of a luteinizing hormone surge-initiating rise. Fertil Steril. 1981 Jul;36(1):50-4.</citation>
    <PMID>7250407</PMID>
  </results_reference>
  <results_reference>
    <citation>Irani M, Robles A, Gunnala V, Reichman D, Rosenwaks Z. Optimal parameters for determining the LH surge in natural cycle frozen-thawed embryo transfers. J Ovarian Res. 2017 Oct 16;10(1):70. doi: 10.1186/s13048-017-0367-7.</citation>
    <PMID>29037231</PMID>
  </results_reference>
  <results_reference>
    <citation>Groenewoud ER, Macklon NS, Cohlen BJ; ANTARCTICA Study Group. The effect of elevated progesterone levels before HCG triggering in modified natural cycle frozen-thawed embryo transfer cycles. Reprod Biomed Online. 2017 May;34(5):546-554. doi: 10.1016/j.rbmo.2017.02.008. Epub 2017 Feb 28.</citation>
    <PMID>28319018</PMID>
  </results_reference>
  <results_reference>
    <citation>Fatemi HM, Kyrou D, Bourgain C, Van den Abbeel E, Griesinger G, Devroey P. Cryopreserved-thawed human embryo transfer: spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil Steril. 2010 Nov;94(6):2054-8. doi: 10.1016/j.fertnstert.2009.11.036. Epub 2010 Jan 25.</citation>
    <PMID>20097333</PMID>
  </results_reference>
  <results_reference>
    <citation>Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Jenkins J, Pellicer A. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod. 2010 Aug;25(8):2092-100. doi: 10.1093/humrep/deq125. Epub 2010 Jun 10.</citation>
    <PMID>20539042</PMID>
  </results_reference>
  <results_reference>
    <citation>Griesinger G, Mannaerts B, Andersen CY, Witjes H, Kolibianakis EM, Gordon K. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertil Steril. 2013 Dec;100(6):1622-8.e1-3. doi: 10.1016/j.fertnstert.2013.08.045. Epub 2013 Sep 29.</citation>
    <PMID>24083873</PMID>
  </results_reference>
  <results_reference>
    <citation>Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update. 2013 Sep-Oct;19(5):433-57. doi: 10.1093/humupd/dmt014. Epub 2013 Jul 4.</citation>
    <PMID>23827986</PMID>
  </results_reference>
  <results_reference>
    <citation>Yding Andersen C, Bungum L, Nyboe Andersen A, Humaidan P. Preovulatory progesterone concentration associates significantly to follicle number and LH concentration but not to pregnancy rate. Reprod Biomed Online. 2011 Aug;23(2):187-95. doi: 10.1016/j.rbmo.2011.04.003. Epub 2011 Apr 28.</citation>
    <PMID>21665546</PMID>
  </results_reference>
  <results_reference>
    <citation>Friis Wang N, Skouby SO, Humaidan P, Andersen CY. Response to ovulation trigger is correlated to late follicular phase progesterone levels: A hypothesis explaining reduced reproductive outcomes caused by increased late follicular progesterone rise. Hum Reprod. 2019 May 1;34(5):942-948. doi: 10.1093/humrep/dez023.</citation>
    <PMID>30927415</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

